UNIDYM, INC. SUBSCRIPTION AGREEMENT SERIES C-1 PREFERRED STOCKSubscription Agreement • August 10th, 2009 • Arrowhead Research Corp • Services-commercial physical & biological research • California
THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of the last date indicated on the signature pages hereto between Unidym, Inc., a Delaware corporation (the “Company”), and the undersigned investor party hereto (“Investor”).
AGREEMENT REGARDING INTELLECTUAL PROPERTY AND WAIVER OF PUT OPTIONSAgreement Regarding Intellectual Property and Waiver of Put Options • August 10th, 2009 • Arrowhead Research Corp • Services-commercial physical & biological research • California
This Agreement Regarding Intellectual Property and Waiver of Put Options (this “Agreement”) is effective, made and entered as of June , 2009 (the “Agreement Date”) by and between Unidym, Inc., a Delaware corporation (“Unidym”), and TEL Venture Capital, Inc., a Delaware corporation (“TEL”). All capitalized terms are defined in Article VII.
IT-101 AGREEMENTIt-101 Agreement • August 10th, 2009 • Arrowhead Research Corp • Services-commercial physical & biological research • Delaware
THIS IT-101 AGREEMENT (“Agreement”), dated as of June 23, 2009 (the “Effective Date”), is by and between CALANDO PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 129 North Hill Avenue, Pasadena, California 91106 (hereinafter referred to as “Calando”), and CERULEAN PHARMA INC., a Delaware corporation, having its principal place of business at 161 First Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “Cerulean”).
PLATFORM AGREEMENTPlatform Agreement • August 10th, 2009 • Arrowhead Research Corp • Services-commercial physical & biological research • Delaware
THIS PLATFORM AGREEMENT (“Agreement”), dated as of June 23, 2009 (the “Effective Date”), is by and between CALANDO PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 129 North Hill Avenue, Pasadena, California 91106 (hereinafter referred to as “Calando”), and CERULEAN PHARMA INC., a Delaware corporation, having its principal place of business at 161 First Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “Cerulean”).
EXCHANGE AGREEMENTExchange Agreement • August 10th, 2009 • Arrowhead Research Corp • Services-commercial physical & biological research • Delaware
THIS EXCHANGE AGREEMENT (this “Agreement”) is dated as of June 25, 2009, by and between Arrowhead Research Corporation, a Delaware corporation (the “Corporation”), and TEL Venture Capital, Inc. (the “Holder”). The Corporation and each Holder are referred to as a “Party” and collectively as the “Parties”.
